The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients-towards a tumor volume-based risk stratification

This study reassesses the diagnostic value of PSMA PET/CT in unfavorable intermediate-risk prostate cancer (PCa) and validates the Prostate Cancer Network the Netherlands (PCNN) subclassification. Men subjected to PSMA PET/CT were analyzed, evaluating the incidence of metastatic disease and its corr...

Full description

Saved in:
Bibliographic Details
Published in:Prostate cancer and prostatic diseases 2024-09
Main Authors: Hagens, Marinus J, Luining, Wietske I, Boevé, Liselotte M S, Knol, Remco J J, Roeleveld, Ton A, Srbljin, Sandra, Weltings, Saskia, Koppes, Jose C C, Oprea-Lager, Daniela E, Vis, André N, van Leeuwen, Pim J, van der Poel, Henk G
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c184t-600e3a079dc39195641103f3940ab238d7b8d82ec250f766476b062daaaa11bc3
container_end_page
container_issue
container_start_page
container_title Prostate cancer and prostatic diseases
container_volume
creator Hagens, Marinus J
Luining, Wietske I
Boevé, Liselotte M S
Knol, Remco J J
Roeleveld, Ton A
Srbljin, Sandra
Weltings, Saskia
Koppes, Jose C C
Oprea-Lager, Daniela E
Vis, André N
van Leeuwen, Pim J
van der Poel, Henk G
description This study reassesses the diagnostic value of PSMA PET/CT in unfavorable intermediate-risk prostate cancer (PCa) and validates the Prostate Cancer Network the Netherlands (PCNN) subclassification. Men subjected to PSMA PET/CT were analyzed, evaluating the incidence of metastatic disease and its correlation with PCNN subgroups. Metastatic disease was identified in 12.4% of patients. Higher PCNN subgroups correlated with increased metastatic potential; odds were significantly lower in low metastatic potential cases (OR: 0.19, 95% CI 0.06-0.62; p = 0.01). Our findings reaffirm PSMA PET/CT's diagnostic value in unfavorable intermediate-risk PCa and validate the PCNN subclassification, reducing scan burden by 48.1%.
doi_str_mv 10.1038/s41391-024-00899-9
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3108763111</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3108763111</sourcerecordid><originalsourceid>FETCH-LOGICAL-c184t-600e3a079dc39195641103f3940ab238d7b8d82ec250f766476b062daaaa11bc3</originalsourceid><addsrcrecordid>eNo9UU1P3TAQtKpW5at_oAfkYy-GdZw49hE90YIEAqmPs-U4mzaQ2A_bAfFj-l_rxwP24F1rZ0b2DCHfOZxwEOo01VxozqCqGYDSmulPZJ_XrWSNBPW5zEI2rFVNtUcOUroHAM01fCV7Qovtrtkn_9Z_kdrNJoZNHG1GjynRMNDb39dn9PZ8fbpa09FTj8_TC-1H-8eHhD1d_GCfQrTdhGWdMc7Yb-ksjumBFrWUy4066x1GurF5RJ8Ty-HZxj5RS_Myh0ifwrTMyDq71XylphwLeBhdOYM_Il8GOyX89tYPyd3P8_Xqgl3d_LpcnV0xx1WdmQRAYaHVvSuG6EbWvBg0CF2D7Sqh-rZTvarQVQ0MrZTFog5k1dtSnHdOHJIfO93y8scFUzbzmBxOk_UYlmQEB9VKwTkv0GoHdeWTKeJginGzjS-Gg9nGYnaxmBKLeY3F6EI6ftNfuuLUB-U9B_EftU2LVg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3108763111</pqid></control><display><type>article</type><title>The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients-towards a tumor volume-based risk stratification</title><source>Springer Link</source><creator>Hagens, Marinus J ; Luining, Wietske I ; Boevé, Liselotte M S ; Knol, Remco J J ; Roeleveld, Ton A ; Srbljin, Sandra ; Weltings, Saskia ; Koppes, Jose C C ; Oprea-Lager, Daniela E ; Vis, André N ; van Leeuwen, Pim J ; van der Poel, Henk G</creator><creatorcontrib>Hagens, Marinus J ; Luining, Wietske I ; Boevé, Liselotte M S ; Knol, Remco J J ; Roeleveld, Ton A ; Srbljin, Sandra ; Weltings, Saskia ; Koppes, Jose C C ; Oprea-Lager, Daniela E ; Vis, André N ; van Leeuwen, Pim J ; van der Poel, Henk G</creatorcontrib><description>This study reassesses the diagnostic value of PSMA PET/CT in unfavorable intermediate-risk prostate cancer (PCa) and validates the Prostate Cancer Network the Netherlands (PCNN) subclassification. Men subjected to PSMA PET/CT were analyzed, evaluating the incidence of metastatic disease and its correlation with PCNN subgroups. Metastatic disease was identified in 12.4% of patients. Higher PCNN subgroups correlated with increased metastatic potential; odds were significantly lower in low metastatic potential cases (OR: 0.19, 95% CI 0.06-0.62; p = 0.01). Our findings reaffirm PSMA PET/CT's diagnostic value in unfavorable intermediate-risk PCa and validate the PCNN subclassification, reducing scan burden by 48.1%.</description><identifier>ISSN: 1365-7852</identifier><identifier>ISSN: 1476-5608</identifier><identifier>EISSN: 1476-5608</identifier><identifier>DOI: 10.1038/s41391-024-00899-9</identifier><identifier>PMID: 39313655</identifier><language>eng</language><publisher>England</publisher><ispartof>Prostate cancer and prostatic diseases, 2024-09</ispartof><rights>2024. The Author(s), under exclusive licence to Springer Nature Limited.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c184t-600e3a079dc39195641103f3940ab238d7b8d82ec250f766476b062daaaa11bc3</cites><orcidid>0000-0003-3419-3368 ; 0000-0001-6699-0201</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39313655$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hagens, Marinus J</creatorcontrib><creatorcontrib>Luining, Wietske I</creatorcontrib><creatorcontrib>Boevé, Liselotte M S</creatorcontrib><creatorcontrib>Knol, Remco J J</creatorcontrib><creatorcontrib>Roeleveld, Ton A</creatorcontrib><creatorcontrib>Srbljin, Sandra</creatorcontrib><creatorcontrib>Weltings, Saskia</creatorcontrib><creatorcontrib>Koppes, Jose C C</creatorcontrib><creatorcontrib>Oprea-Lager, Daniela E</creatorcontrib><creatorcontrib>Vis, André N</creatorcontrib><creatorcontrib>van Leeuwen, Pim J</creatorcontrib><creatorcontrib>van der Poel, Henk G</creatorcontrib><title>The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients-towards a tumor volume-based risk stratification</title><title>Prostate cancer and prostatic diseases</title><addtitle>Prostate Cancer Prostatic Dis</addtitle><description>This study reassesses the diagnostic value of PSMA PET/CT in unfavorable intermediate-risk prostate cancer (PCa) and validates the Prostate Cancer Network the Netherlands (PCNN) subclassification. Men subjected to PSMA PET/CT were analyzed, evaluating the incidence of metastatic disease and its correlation with PCNN subgroups. Metastatic disease was identified in 12.4% of patients. Higher PCNN subgroups correlated with increased metastatic potential; odds were significantly lower in low metastatic potential cases (OR: 0.19, 95% CI 0.06-0.62; p = 0.01). Our findings reaffirm PSMA PET/CT's diagnostic value in unfavorable intermediate-risk PCa and validate the PCNN subclassification, reducing scan burden by 48.1%.</description><issn>1365-7852</issn><issn>1476-5608</issn><issn>1476-5608</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9UU1P3TAQtKpW5at_oAfkYy-GdZw49hE90YIEAqmPs-U4mzaQ2A_bAfFj-l_rxwP24F1rZ0b2DCHfOZxwEOo01VxozqCqGYDSmulPZJ_XrWSNBPW5zEI2rFVNtUcOUroHAM01fCV7Qovtrtkn_9Z_kdrNJoZNHG1GjynRMNDb39dn9PZ8fbpa09FTj8_TC-1H-8eHhD1d_GCfQrTdhGWdMc7Yb-ksjumBFrWUy4066x1GurF5RJ8Ty-HZxj5RS_Myh0ifwrTMyDq71XylphwLeBhdOYM_Il8GOyX89tYPyd3P8_Xqgl3d_LpcnV0xx1WdmQRAYaHVvSuG6EbWvBg0CF2D7Sqh-rZTvarQVQ0MrZTFog5k1dtSnHdOHJIfO93y8scFUzbzmBxOk_UYlmQEB9VKwTkv0GoHdeWTKeJginGzjS-Gg9nGYnaxmBKLeY3F6EI6ftNfuuLUB-U9B_EftU2LVg</recordid><startdate>20240923</startdate><enddate>20240923</enddate><creator>Hagens, Marinus J</creator><creator>Luining, Wietske I</creator><creator>Boevé, Liselotte M S</creator><creator>Knol, Remco J J</creator><creator>Roeleveld, Ton A</creator><creator>Srbljin, Sandra</creator><creator>Weltings, Saskia</creator><creator>Koppes, Jose C C</creator><creator>Oprea-Lager, Daniela E</creator><creator>Vis, André N</creator><creator>van Leeuwen, Pim J</creator><creator>van der Poel, Henk G</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3419-3368</orcidid><orcidid>https://orcid.org/0000-0001-6699-0201</orcidid></search><sort><creationdate>20240923</creationdate><title>The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients-towards a tumor volume-based risk stratification</title><author>Hagens, Marinus J ; Luining, Wietske I ; Boevé, Liselotte M S ; Knol, Remco J J ; Roeleveld, Ton A ; Srbljin, Sandra ; Weltings, Saskia ; Koppes, Jose C C ; Oprea-Lager, Daniela E ; Vis, André N ; van Leeuwen, Pim J ; van der Poel, Henk G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c184t-600e3a079dc39195641103f3940ab238d7b8d82ec250f766476b062daaaa11bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hagens, Marinus J</creatorcontrib><creatorcontrib>Luining, Wietske I</creatorcontrib><creatorcontrib>Boevé, Liselotte M S</creatorcontrib><creatorcontrib>Knol, Remco J J</creatorcontrib><creatorcontrib>Roeleveld, Ton A</creatorcontrib><creatorcontrib>Srbljin, Sandra</creatorcontrib><creatorcontrib>Weltings, Saskia</creatorcontrib><creatorcontrib>Koppes, Jose C C</creatorcontrib><creatorcontrib>Oprea-Lager, Daniela E</creatorcontrib><creatorcontrib>Vis, André N</creatorcontrib><creatorcontrib>van Leeuwen, Pim J</creatorcontrib><creatorcontrib>van der Poel, Henk G</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Prostate cancer and prostatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hagens, Marinus J</au><au>Luining, Wietske I</au><au>Boevé, Liselotte M S</au><au>Knol, Remco J J</au><au>Roeleveld, Ton A</au><au>Srbljin, Sandra</au><au>Weltings, Saskia</au><au>Koppes, Jose C C</au><au>Oprea-Lager, Daniela E</au><au>Vis, André N</au><au>van Leeuwen, Pim J</au><au>van der Poel, Henk G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients-towards a tumor volume-based risk stratification</atitle><jtitle>Prostate cancer and prostatic diseases</jtitle><addtitle>Prostate Cancer Prostatic Dis</addtitle><date>2024-09-23</date><risdate>2024</risdate><issn>1365-7852</issn><issn>1476-5608</issn><eissn>1476-5608</eissn><abstract>This study reassesses the diagnostic value of PSMA PET/CT in unfavorable intermediate-risk prostate cancer (PCa) and validates the Prostate Cancer Network the Netherlands (PCNN) subclassification. Men subjected to PSMA PET/CT were analyzed, evaluating the incidence of metastatic disease and its correlation with PCNN subgroups. Metastatic disease was identified in 12.4% of patients. Higher PCNN subgroups correlated with increased metastatic potential; odds were significantly lower in low metastatic potential cases (OR: 0.19, 95% CI 0.06-0.62; p = 0.01). Our findings reaffirm PSMA PET/CT's diagnostic value in unfavorable intermediate-risk PCa and validate the PCNN subclassification, reducing scan burden by 48.1%.</abstract><cop>England</cop><pmid>39313655</pmid><doi>10.1038/s41391-024-00899-9</doi><orcidid>https://orcid.org/0000-0003-3419-3368</orcidid><orcidid>https://orcid.org/0000-0001-6699-0201</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1365-7852
ispartof Prostate cancer and prostatic diseases, 2024-09
issn 1365-7852
1476-5608
1476-5608
language eng
recordid cdi_proquest_miscellaneous_3108763111
source Springer Link
title The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients-towards a tumor volume-based risk stratification
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T18%3A45%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20appropriateness%20of%20PSMA%20PET/CT%20in%20newly%20diagnosed%20unfavorable%20intermediate-risk%20prostate%20cancer%20patients-towards%20a%20tumor%20volume-based%20risk%20stratification&rft.jtitle=Prostate%20cancer%20and%20prostatic%20diseases&rft.au=Hagens,%20Marinus%20J&rft.date=2024-09-23&rft.issn=1365-7852&rft.eissn=1476-5608&rft_id=info:doi/10.1038/s41391-024-00899-9&rft_dat=%3Cproquest_cross%3E3108763111%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c184t-600e3a079dc39195641103f3940ab238d7b8d82ec250f766476b062daaaa11bc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3108763111&rft_id=info:pmid/39313655&rfr_iscdi=true